Skip to main content

Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology - Conference Highlights ASH

New Orleans, LA—An investigational monoclonal antibody may be of benefit in treating patients with multicentric Castleman’s disease, a potentially fatal, incurable disorder with high morbidity believed to be partially mediated by the overproduction of interleukin-6 that results in the dangerous overgrowth of cells in the lymph nodes. The drug, siltuximab, blocks the function of interleukin-6 and ideally ameliorates this uncontrolled cell growth and controls other inflammatory disease symptoms.

In a phase 2 study presented at ASH 2013, and featured in a press briefing, investigators randomly assigned 70 patients with multicentric Castleman’s disease to siltuximab or to placebo, plus best supportive care. Of the patients treated with siltuximab, 34% achieved a durable tumor and symptom response compared with none of the patients in the placebo arm.

At baseline, patients reported fatigue (86%), malaise (61%), night sweats (52%), peripheral sensory neuropathy (38%), anorexia (37%), and pruritus (37%). The symptoms completely resolved in 25% of the siltuximab group for a median of 1.3 years, but placebo recipients had no resolution of symptoms. The median time to next treatment was not reached in the siltuximab arm versus a time of 280 days in the placebo arm.

Despite a 2-fold longer duration of treatment with siltuximab, rates of adverse events were similar between the arms, reported Raymond S. Wong, MBChB, MD, a radiation oncologist at the Prince of Wales Hospital, Chinese University of Hong Kong, China.

“If siltuximab gains regulatory approval, this experimental therapy could become the first globally approved treatment for this incurable disease and could potentially transform how patients are treated in the future,” Dr Wong predicted.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on February 25, 2020 in Conference Highlights ASH
Improving the Standard of Care
R. Donald Harvey, PharmD, FCCP, BCOP
Videos published on January 5, 2016 in Conference Highlights ASH
Real-World Data on Primary Treatment for Mantle-Cell Lymphoma 2000-2011 – A Nordic Lymphoma Group Observational Study
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Oral Arsenic Trioxide-Based Regimen as Salvage Treatment for Relapsed or Refractory Mantle-Cell Lymphoma
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma in Need of Palliative Therapy
Conference Correspondent published on April 15, 2014 in Conference Highlights ASH
Last modified: August 30, 2021